5-azacitidine and Thalidomide for patients with Myelodysplastic Syndromes to assess safety and efficacy

DOI number 10.58109/wjn4-hj03
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

Melita Kenealy (Peter MacCallum Cancer Centre)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 80 patients with newly diagnosed MDS, utilising treatment with a combination of 5-azacitidine and Thalidomide
  • Dataset includes
  • Demographic data
  • Diagnostic data
  • Treatment data
  • Outcome data Eg transfusion requirements, QoL

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)


ANZCTR Reference ACTRN12607000283471
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au